AstraZeneca has acquired preclinical U.S. biotech company Omniose following a three-year research collaboration, absorbing the firm into its Infectious Disease Unit. The acquisition integrates Omniose's proprietary bioconjugation platform, which simplifies bacterial vaccine manufacturing inside single E. coli cells. The deal bolsters AstraZeneca's vaccine portfolio following the 2024 withdrawal of its COVID-19 shot, supporting broader pipeline efforts across cancer and antimicrobial-resistant bacterial targets.
AstraZeneca acquires biotech firm Omniose
- ▪AstraZeneca acquired St. Louis-based preclinical biotech firm Omniose, folding it into AstraZeneca's Infectious Disease Unit as a wholly owned subsidiary
- ▪The acquisition of Omniose by AstraZeneca followed a three-year exclusive research collaboration between the two companies, with financial terms of the deal undisclosed
Omniose's bioconjugation platform technology
- ▪Bioconjugation streamlines conjugate vaccine manufacturing compared to traditional chemical attachment methods, offering a simpler approach designed to produce higher-quality vaccines targeting bacterial infections
- ▪Omniose's bioconjugation platform enables single E. coli cells to produce and link bacterial polysaccharide antigens to engineered carrier proteins in a single process
Story comments
Loading comments…